U.S. Banks Stock News

Business First Bancshares has delivered a solid 65.7% return over the past three years, while the latest intrinsic value work using the Excess Returns model points to the stock trading at a meaningful discount to that estimate, even as market multiples look roughly in line with peers. A 65.7% share price gain over three years suggests the market has already recognised value in Business First Bancshares. Yet current analytics still point to room between price and intrinsic value. For bank...

Mastercard (MA) is back in focus after appointing nearly 20-year company veteran Yasemin Bedir as president of its Eastern Europe, Middle East and Africa unit, a region that currently generates significant revenue. Mastercard shares recently approached record levels before a slight pullback, and the stock is now trading at US$598.47 after a 90 day share price return of 21.21% and a 30 day share price return of 8.48%. The 5 year total shareholder return of 76.34% points to momentum that has...

McEwen Inc. recently announced the past retirement of Chief Operating Officer William Shaver, a mining veteran with over 55 years of experience, alongside leadership promotions focused on operations, development projects and permitting to support its long-term production ambitions. An interesting detail is that Shaver will remain on the board of McEwen Copper, helping preserve technical continuity as McEwen advances its copper portfolio and broader growth plans. Next, we will examine how...

PPG Industries (PPG) stock is drawing attention after the company reshaped leadership across its three global business segments, with new senior executives set to assume expanded responsibilities from September 1, 2026. Against this leadership reshuffle, PPG Industries’ recent share price performance has been mixed. The 1-day share price return is 0.68% and the 7-day share price return is 0.44%, but the 30-day share price return declined 3.42%. The 1-year total shareholder return is 4.71%,...

CoStar Group (CSGP) is back in focus after its latest quarterly report showed revenue of US$925 million and adjusted EBITDA of US$184 million, with profitability metrics improving despite guidance that tracked closely with peers. Despite the stronger profitability profile, CoStar Group’s share price has been under pressure, with the stock down 51.07% on a year to date basis and the 1 year total shareholder return declining 64.07%. However, a 10.18% 1 month share price return hints at...

Reinsurance Group of America (RGA) is back in focus after recent coverage highlighted its P/E and P/B ratios relative to industry peers, along with an earnings outlook that has encouraged renewed investor interest. At a share price of US$246.55, Reinsurance Group of America has seen momentum build, with a 90 day share price return of 20.53% and a year to date share price return of 21.19%. The 1 year total shareholder return of 29.31% and 5 year total shareholder return of 132.03% suggest...

Pulse Biosciences (PLSE) has drawn attention after recent share price strength, with the stock up over the past month and over the past three months. Investors are assessing what the latest moves imply for future expectations. For context, the current share price of Pulse Biosciences is US$48.10. The stock has logged a 46.69% 30 day share price return and a 94.42% 90 day share price return, while the 1 year total shareholder return of 203.47% and a very large 3 year total shareholder return...

Central banks in Europe are still talking about further rate moves as they watch energy markets, which keeps attention on hard assets that make AI possible. While software headlines ebb and flow, the physical AI infrastructure theme links directly to power, cooling and connectivity that data centers rely on. This article looks at three AI infrastructure stocks from our screener that illustrate how this theme is playing out. The three stocks below are just a sample from this AI infrastructure...

TG Therapeutics recently raised its 2026 revenue guidance to about US$950 million, citing strong momentum from BRIUMVI, which delivered US$227.7 million in Q2 2026 sales. This shift highlights how a single high-performing therapy can rapidly reshape the company’s revenue outlook and heighten investor focus on execution and durability of BRIUMVI demand. Next, we’ll examine how the higher 2026 revenue guidance driven by BRIUMVI’s performance may influence TG Therapeutics’ broader investment...

Corsair Gaming recently drew attention as analysts highlighted sustained demand for its gaming hardware and creator-focused peripherals, alongside expectations for stronger earnings despite sector pressures like inflation and regulatory changes. An interesting angle is how this creator-focused product demand is being viewed as a buffer against broader industry headwinds, supporting Corsair’s perceived resilience. We’ll now examine how this sustained demand for gaming and creator peripherals...

Coherent has delivered a very large 3 year share price gain, yet current valuation checks send a mixed message as the Discounted Cash Flow (DCF) estimate screens the stock as undervalued while market based multiples look closer to in line with peers. The stock is up roughly 7x over 3 years, which puts extra focus on whether that surge is already pricing in much of the growth investors expect. Excitement around Coherent's role in AI infrastructure and optical communications can support...

Oklo (OKLO) is back in focus after a cluster of milestones, including first criticality at its Groves Isotope Test Reactor on private land, new Department of Energy safety approvals, initial technical services revenue and a planned US$1.68b fuel recycling facility. Despite those milestones, Oklo’s share price has been under pressure, with the stock down 46.53% year to date based on share price return and the 1-year total shareholder return declining 43.17%, although the 3-year and 5-year...

ACADIA Pharmaceuticals (ACAD) is in focus after the European Commission granted marketing authorization for DAYBU, trofinetide, as the first approved Rett syndrome treatment in the European Union and associated European Economic Area countries. Despite the DAYBU approval, ACADIA Pharmaceuticals’ share price slipped 3.24% over the last trading day and 2.09% over the past week, although a 36.75% 90 day share price return and 67.21% five year total shareholder return indicate momentum that has...

Zeta Global Holdings (ZETA) is back on investor radars after confirming presentations at Goldman Sachs and Citi conferences. These events will spotlight its AI infrastructure, trillion signal data engine, and the expanding Athena product suite. The recent conference schedule lands after a sharp run up in Zeta Global Holdings’ share price, with a 30 day share price return of 36.11% and a 90 day gain of 39.89%. Over the longer term, total shareholder returns of 41.72% over one year and a very...

IPC Systems recently announced that BGC Group has selected its IPC One platform as the firm’s global communications and connectivity backbone, deepening a long-standing relationship to support BGC’s trading operations and growth strategy. This move highlights how BGC is prioritizing a flexible, cloud-enabled infrastructure tailored to the needs of global financial markets to underpin its ongoing transformation. We’ll now examine how BGC’s choice of IPC One as its core communications platform...

Voya Financial (VOYA) is back in focus after the District of Columbia selected the company to provide recordkeeping and administration for its 401(a) and 457(b) public retirement plans. For investors tracking the share price, Voya Financial has moved higher in recent months, with a 90 day share price return of 26.8% and a year to date gain of 34.31%. The 1 year total shareholder return of 37.17% points to momentum that has been building rather than fading as the company adds mandates like the...

Element Solutions stock has delivered a strong 3 year return, yet investors are getting mixed messages on value, with the intrinsic value estimate pointing to a discount while market multiples suggest the shares are not cheap. Over the past 3 years, Element Solutions has returned 81.0%, which puts more focus on whether the current valuation still leaves room for a reasonable margin of safety. The valuation case can benefit from consistent cash flow generation. However, any pressure on...

As Washington weighs tougher secondary sanctions on Chinese entities tied to Iran and Middle East supply routes face renewed pressure, energy trade routes and fuel flows are being quietly redrawn. That can create sharp winners and losers. Some companies with refining or LNG infrastructure outside China could see very different demand patterns as cargoes are rerouted. This article walks through three stocks exposed to these shocks and explains what informed investors are watching now. The...

Jacobs Solutions Inc. has confirmed that, effective August 10, 2026, Shannon Miller transitioned out of her role as President, Strategy, Growth & Digital and will remain as Special Advisor to the CEO until her departure, expected by October 3, 2026. This leadership change comes shortly after the company reported Q3 2026 results highlighting higher adjusted EPS and strong revenue growth supported by AI-driven data-center demand. Next, we’ll examine how Miller’s transition and the AI-fueled...

Earlier this month, Illumina entered into a new US$1.00 billion senior unsecured five-year revolving credit facility, replacing its 2023 agreement, with variable-rate borrowing options, covenant limits on leverage and subsidiary indebtedness, and no amounts drawn as of the announcement. The updated credit line effectively refreshes Illumina’s liquidity backstop and financing flexibility at a time when its sequencing-led clinical business is supporting stronger revenue and earnings...

Earlier this year, Revolution Medicines held a special call to discuss RASONQUE™ (daraxonrasib), described as the first broad RAS‑targeted medicine for metastatic pancreatic cancer and other company updates. This focus on a broad RAS‑targeted therapy in a hard‑to‑treat tumor type highlights how Revolution Medicines is trying to translate its RAS(ON) science into real‑world clinical impact. We’ll now examine how this RASONQUE™ pancreatic cancer update fits into Revolution Medicines’ broader...

KLA Corporation recently reported that rising investments in AI infrastructure, advanced packaging and leading-edge semiconductor manufacturing are lifting demand for its process-control and inspection systems, with management highlighting expectations for significant advanced-packaging revenue growth in 2026. An interesting angle is that KLA’s expanding advanced-packaging franchise is not only driving higher equipment shipments but also enlarging its installed base, supporting a growing...

Marvell Technology has delivered a very strong share price run over the past few years, while the current checks suggest the stock is not a clear bargain and may already be pricing in a lot of good news. The Discounted Cash Flow (DCF) intrinsic value estimate sits close to the market price, while traditional market multiples point to an overvalued profile. Over the last 3 years, Marvell Technology has returned 332.3%, which puts extra attention on whether recent gains already reflect...

Visa (NYSE: V) and Bluefin announced a unified in person payment acceptance solution that combines secure point to point encryption, tokenization, and Visa's global payment infrastructure. The new offering is designed to simplify secure card present payments for merchants while using Bluefin's encryption technology alongside Visa's enterprise payment capabilities. The partnership targets large enterprises and global merchants that manage complex in store payment environments and security...